$AMBS is moving closer to marketable assets in orphan-drug designated therapy research, and shares appear to be hanging around at extremely cheap levels, especially given the latest press on the name.
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!